A detailed history of Schonfeld Strategic Advisors LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 46,094 shares of MDGL stock, worth $14.4 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
46,094
Previous 24,460 88.45%
Holding current value
$14.4 Million
Previous $6.85 Million 42.76%
% of portfolio
0.07%
Previous 0.05%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$212.22 - $292.96 $4.59 Million - $6.34 Million
21,634 Added 88.45%
46,094 $9.78 Million
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $4.73 Million - $7.14 Million
24,460 New
24,460 $6.85 Million
Q4 2023

Feb 14, 2024

SELL
$120.4 - $237.13 $7.11 Million - $14 Million
-59,077 Reduced 82.58%
12,458 $2.88 Million
Q3 2023

Nov 14, 2023

BUY
$146.04 - $225.78 $7.55 Million - $11.7 Million
51,670 Added 260.11%
71,535 $10.4 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $2.03 Million - $3.1 Million
-9,939 Reduced 33.35%
19,865 $4.59 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $3.51 Million - $4.67 Million
15,204 Added 104.14%
29,804 $7.22 Million
Q4 2022

Feb 14, 2023

SELL
$58.39 - $296.54 $3.16 Million - $16.1 Million
-54,136 Reduced 78.76%
14,600 $4.24 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $3.42 Million - $4.48 Million
56,389 Added 456.7%
68,736 $4.47 Million
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $716,619 - $1.24 Million
12,347 New
12,347 $884,000
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $497,700 - $907,330
-8,905 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $224,615 - $295,254
3,105 Added 53.53%
8,905 $754,000
Q3 2021

Nov 16, 2021

SELL
$78.35 - $105.02 $31,339 - $42,008
-400 Reduced 6.45%
5,800 $463,000
Q2 2021

Aug 16, 2021

SELL
$97.2 - $137.59 $2.36 Million - $3.34 Million
-24,254 Reduced 79.64%
6,200 $604,000
Q1 2021

May 17, 2021

BUY
$108.54 - $125.2 $3.31 Million - $3.81 Million
30,454 New
30,454 $3.56 Million
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $716,160 - $869,985
-6,507 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$99.78 - $124.21 $137,496 - $171,161
-1,378 Reduced 17.48%
6,507 $1,000
Q2 2020

Aug 14, 2020

SELL
$60.13 - $125.71 $2,164 - $4,525
-36 Reduced 0.45%
7,885 $893,000
Q1 2020

May 15, 2020

BUY
$66.76 - $93.49 $528,805 - $740,534
7,921 New
7,921 $529,000
Q2 2019

Aug 14, 2019

SELL
$91.13 - $142.5 $246,051 - $384,750
-2,700 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $2.92 Million - $4.06 Million
-28,200 Reduced 91.26%
2,700 $338,000
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $2.75 Million - $6.25 Million
-29,000 Reduced 48.41%
30,900 $3.48 Million
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $11.2 Million - $16.2 Million
54,000 Added 915.25%
59,900 $12.8 Million
Q2 2018

Aug 14, 2018

BUY
$101.55 - $313.9 $214,067 - $661,701
2,108 Added 55.59%
5,900 $1.65 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $353,983 - $565,159
3,792 New
3,792 $443,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.34B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.